122 related articles for article (PubMed ID: 38782376)
1. Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain-cleavable peptide linker.
Wang Y; Wei L; Liu Y; Liu C; Hou M; Zhou L; Wang L; Li H; Qiu Y; JingMa
J Appl Toxicol; 2024 May; ():. PubMed ID: 38782376
[TBL] [Abstract][Full Text] [Related]
2. UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies.
Ma L; Yu Q; Zhuang M; Yang C; Liu Y; Li Y; Liu C; Shen X; Chang Y
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398527
[TBL] [Abstract][Full Text] [Related]
3. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
4. Legumain-cleavable 4-arm poly(ethylene glycol)-doxorubicin conjugate for tumor specific delivery and release.
Zhou H; Sun H; Lv S; Zhang D; Zhang X; Tang Z; Chen X
Acta Biomater; 2017 May; 54():227-238. PubMed ID: 28315495
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.
Liu C; Sun C; Huang H; Janda K; Edgington T
Cancer Res; 2003 Jun; 63(11):2957-64. PubMed ID: 12782603
[TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
7. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
Hopewel JW; Duncan R; Wilding D; Chakrabarti K
Hum Exp Toxicol; 2001 Sep; 20(9):461-70. PubMed ID: 11776408
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
11. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
12. Toxicological evaluation of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine (VNP40101M), a novel alkylating agent with potential antitumor activity, with intravenous administration in rats and dogs.
Lee KC; Almassian B; Noveroske J
Int J Toxicol; 2002; 21(1):23-38. PubMed ID: 11936896
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers.
Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
Xenobiotica; 2024 May; ():1-13. PubMed ID: 38738708
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of radioactive/fluorescent peptide probes for imaging of legumain activity.
Fuchigami T; Itagaki K; Ishikawa N; Yoshida S; Nakayama M
Bioorg Med Chem Lett; 2019 Oct; 29(19):126629. PubMed ID: 31445852
[TBL] [Abstract][Full Text] [Related]
16. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Anticancer Efficacy and Toxicity Studies of a Novel Polymer Conjugate N-Acetyl Glucosamine (NAG)-PEG-Doxorubicin for Targeted Cancer Therapy.
Pawar S; Mahajan K; Vavia P
AAPS PharmSciTech; 2017 Nov; 18(8):3021-3033. PubMed ID: 28497240
[TBL] [Abstract][Full Text] [Related]
18. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1).
Duncan R; Coatsworth JK; Burtles S
Hum Exp Toxicol; 1998 Feb; 17(2):93-104. PubMed ID: 9506260
[TBL] [Abstract][Full Text] [Related]
19. Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity.
Dragojevic S; Ryu JS; Hall ME; Raucher D
Molecules; 2022 May; 27(11):. PubMed ID: 35684309
[TBL] [Abstract][Full Text] [Related]
20. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Zou Y; Priebe W; Stephens LC; Perez-Soler R
Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
